Using immunohistochemistry method, we detected HDAC1 and p21, which was considered as a HDAC target22 and was verified to be altered in our in vitro data, in paraffin-embedded tissues from 59 paclitaxel-treated NSCLC patients. The gene discussed is HDAC1; the disease is non-small cell lung carcinoma.